Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 12, 2023
Share
Ever Supreme Bio Technology Co., Ltd reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 226.84 million compared to TWD 171.65 million a year ago. Net income was TWD 274.91 million compared to TWD 38.24 million a year ago. Basic earnings per share from continuing operations was TWD 3.7 compared to TWD 0.51 a year ago. Diluted earnings per share from continuing operations was TWD 3.68 compared to TWD 0.51 a year ago.
For the nine months, sales was TWD 503.42 million compared to TWD 447.77 million a year ago. Net income was TWD 441.3 million compared to TWD 70.54 million a year ago. Basic earnings per share from continuing operations was TWD 5.9 compared to TWD 0.94 a year ago. Diluted earnings per share from continuing operations was TWD 5.88 compared to TWD 0.94 a year ago.
Ever Supreme Bio Technology Co., Ltd. is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sales of stem cell products and immune cell products. The Company has three main products. ADCV01 is an autologous dendritic cell tumor vaccine product, which is currently in the phaseII of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product and a new drug for the treatment of myocardial infarction, which is approved by the United States Food and Drug Administration (FDA) clinical phaseI and is currently applying for the phaseI of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product, which is used to treat acute ischemic stroke and is currently in the United States FDA for clinical phase I. The Company plans to develop new products and services including mesenchymal stem cells for the treatment of multiple sclerosis.
EVER SUPREME BIO TECHNOLOGY CO., LTD 
